1. Acknowledgement to Referees

   Acknowledgement to Referees 05 November 2019 Pages: 1413 - 1415

2. Could or Should We Use MCDA in the French HTA Process?

   • Salah Ghabri
   • Jean-Michel Josselin
   • Benoît Le Maux

   Editorial 30 September 2019 Pages: 1417 - 1419

3. Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma: A Systematic Review

   • Shuangshuang Fu
   • Chi-Fang Wu
   • David R. Lairson

   Review Article 07 August 2019 Pages: 1421 - 1449

   

4. Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design

   • Daniel M. Sugrue
   • Thomas Ward
   • Heleen G. M. van Haalen

   Systematic Review Open access 30 September 2019 Pages: 1451 - 1468

   

5. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments

   • Fernando Antonanzas
   • Carmelo Juárez-Castelló
   • Roberto Rodríguez-Ibeas

   Systematic Review 18 September 2019 Pages: 1469 - 1483

   

6. Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort

   • Michael Laxy
   • Verena Maria Schöning
   • Katharina Kähm

   Original Research Article 27 July 2019 Pages: 1485 - 1494

   

7. Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II—An Updated Analysis of SEER-Medicare Data

   • Ya-Chen Tina Shih
   • Ying Xu
   • Daniel M. Geynisman

   Original Research Article 08 July 2019 Pages: 1495 - 1507

   

8. Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease

   • Heather Catt
   • Keith Bodger
   • Dyfrig A. Hughes

   Original Research Article 02 August 2019 Pages: 1509 - 1523

   

9. A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis

   • Sandjar Djalalov
   • Jaclyn Beca
   • Jeffrey S. Hoch

   Original Research Article 01 October 2019 Pages: 1525 - 1536

   

10. Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies

    • Venediktos Kapetanakis
    • Thibaud Prawitz
    • Murtuza Bharmal

    Original Research Article 26 September 2019 Pages: 1537 - 1551

    

11. Correction to: Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review

    • Dongzhe Hong
    • Lei Si
    • Lizheng Shi

    Correction 04 September 2019 Pages: 1553 - 1553